Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]
Annexon (NASDAQ:ANNX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome [Yahoo! Finance]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]